Global Kidney Cancer Drugs Industry

NEW YORK, July 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Kidney Cancer Drugs Industry

http://www.reportlinker.com/p0611069/Global-Kidney-Cancer-Drugs-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on 'Kidney Cancer Drugs' provides market analytics specifically for the "Renal Cell Carcinoma" (RCC) market, owing to its predominance among the various types of kidney cancers. The market for Renal Cell Carcinoma (RCC) drugs is analyzed by the two major drug classes, which include: Multikinase Inhibitors, and Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other emerging drug classes). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 19 companies including many key and niche players such as AVEO Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co., Onyx Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck-Serono, Novartis AG, Pfizer, Inc., and WILEX AG. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Read more from the original source:
Global Kidney Cancer Drugs Industry